Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

GENE THERAPY

Safety questions for AAV gene therapy

Nature Biotechnology volume 39, pages 24–26 (2021)Cite this article

Subjects

A long-term study of AAV therapy in dogs finds clonal expansions and vector integrations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Vectors, results and integration analyses for AAV F8 gene therapy.

References

  1. Nguyen, G. N. Nat. Biotechnol. https://doi.org/10.1038/s41587-020-0741-7 (2020).

  2. Chandler, R. J., Sands, M. S. & Venditti, C. P. Hum. Gene Ther. 28, 314–322 (2017).

    Article  CAS  Google Scholar 

  3. Donsante, A. et al. Science 317, 477 (2007).

    Article  CAS  Google Scholar 

  4. Chandler, R. J. et al. J. Clin. Invest. 125, 870–880 (2015).

    Article  Google Scholar 

  5. Wang, P. R. et al. Proc. Natl. Acad. Sci. USA 109, 11264–11269 (2012).

    Article  CAS  Google Scholar 

  6. Zhong, L. et al. Hum. Gene Ther. 24, 520–525 (2013).

    Article  CAS  Google Scholar 

  7. Nault, J. C. et al. Nat. Genet. 47, 1187–1193 (2015).

    Article  CAS  Google Scholar 

  8. La Bella, T. et al. Gut 69, 737–747 (2020).

    Article  Google Scholar 

  9. Logan, G. J. et al. Nat. Genet. 49, 1267–1273 (2017).

    Article  CAS  Google Scholar 

  10. Salerno, D. et al. Gut 69, 737–747 (2020).

    Article  Google Scholar 

  11. Rumachik, N. G. et al. Mol. Ther. Methods Clin. Dev. 18, 98–118 (2020).

    Article  CAS  Google Scholar 

  12. Tran, N. T. et al. Mol. Ther. Methods Clin. Dev. 18, 639–651 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

    Charles P. Venditti

Authors
  1. Charles P. Venditti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles P. Venditti.

Ethics declarations

Competing interests

C.P.V. is a named inventor on several patents that have been filed by the NIH on his behalf, and his laboratory has received funding from Moderna, Selecta Biosciences, AskBio and LogicBio Therapeutics to support preclinical research.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Venditti, C.P. Safety questions for AAV gene therapy. Nat Biotechnol 39, 24–26 (2021). https://doi.org/10.1038/s41587-020-00756-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-020-00756-9

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research